Real-world efficacy and safety of Erenumab: a prospective study of 80 patients in a specialized headache center

Abstract

Anti-CGRP monoclonal antibodies and particularly Erenumab become the first migraine-specific treatment and have demonstrated high efficacy and safety in the randomized clinical trials.Aim. The aim of this study is the prospective evaluation of the efficacy and safety of Erenumab in patients with episodic migraine (EM) and chronic migraine (CM).Material and мethods. We recruited patients aged 18–85 diagnosed with EM and CM according to the International Classification of Headache Disorders, 3rd edition. All patients were from November 2020 to December 2021. Demographic data, history of migraine and previous migraine treatment were collected for each patient. All patients filled out scales and questionnaires, headache frequency dynamics was followed up monthly with headache diaries.Results. After three months of treatment reduction marked reduction of headache frequency was observed, and 53.5% of patients became ≥ 50% responders. After six months of treatment a further increase in the effect was observed: 57% of patients had at least a two-fold reduction in headache frequency, 74% of patients became ≥ 30% responders. Constipation was observed in 3.8% of patients.Conclusion. Erenumab is safe and effective in the treatment of moderate- and high-frequency EM, CM and medication-overuse headache.